REGENXBIO Inc. business relationships
Companies named in REGENXBIO Inc.’s 10-K filed 2026-03-05, and public companies whose annual reports name REGENXBIO Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in REGENXBIO Inc.’s annual report 16
“We recognize royalty revenue from net sales of Zolgensma and Itvisma in the period in which the underlying products are sold by Novartis Gene Therapies, which in certain cases may require us to estimate royalty revenue for periods of net sales which have not yet been reported to us.” SEC filing
“One customer (Novartis Gene Therapies) accounted for approximately 98% of our total revenues for the year ended December 31, 2024.” SEC filing
“We have no obligation to repay any amounts to HCR if total future Zolgensma and Itvisma royalty payments from Novartis are not sufficient to repay these amounts.” SEC filing
“Zolgensma and Itvisma are licensed products under our license agreement with Novartis Gene Therapies for the development and commercialization of treatments for SMA using the NAV Technology Platform.” SEC filing
“...ation payable to the Company under specified license agreements (collectively, the Royalty Interest), including (i) the Novartis License for Zolgensma and Itvisma, (ii) the collaboration and license agreement with Nippon Shinyaku for RGX-121 and RGX-111, and (iii) NAV Technology Platform license agr...” SEC filing
“...aku for RGX-121 and RGX-111, and (iii) NAV Technology Platform license agreements with Rocket Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. Zolgensma and Itvisma royalties earned under the Novartis License shall only be included in the Royalty Interest after full repayment of the applicab...” SEC filing
“Our license agreement with Penn provides that should the rights Penn licensed to GSK ever revert to Penn, such rights shall automatically be included in our license agreement with Penn.” SEC filing
“The last to expire patent under the GSK license agreement, absent patent term” SEC filing
“...cense agreement with Nippon Shinyaku for RGX-121 and RGX-111, and (iii) NAV Technology Platform license agreements with Rocket Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. Zolgensma and Itvisma royalties earned under the Novartis License shall only be included in the Royalty Interest aft...” SEC filing
“...ded that the units of account for the delivery of the functional intellectual property license and the manufacturing of commercial supply for sales of ABBV-RGX-314 outside the United States should be accounted for as revenue under ASC 606, as AbbVie is deemed to be a customer for these transactions.” SEC filing
“The intellectual property licensed to AbbVie includes the rights to certain patents, data, know-how and other rights developed and owned by the Company, as well as other intellectual property rights exclusively licensed by the Company from various third parties.” SEC filing
“Under the terms of our Collaboration and License Agreement with AbbVie (the AbbVie Collaboration and License Agreement), we received an upfront payment of $370 million.” SEC filing
“Topline data from these trials are expected to be shared in the fourth quarter of 2026 in partnership with AbbVie.” SEC filing
“Manufacturing expenses will be allocated between the parties in accordance with the terms of the AbbVie Collaboration Agreement and mutually agreed supply agreements.” SEC filing
“We have licensed certain exclusive rights to the SCS Microinjector ® from Clearside Biomedical, Inc. (Clearside) to deliver gene therapy treatments to the suprachoroidal space of the eye.” SEC filing
“In August 2019, the Company entered into an option and license agreement with Clearside Biomedical, Inc. (Clearside) pursuant to which the Company was granted an option to exclusively license the worldwide rights to certain patents related to Clearside's proprietary, in-office SCS Microinjector ® fo...” SEC filing
Companies whose annual reports name REGENXBIO Inc. 5
“The use of AAV9 to deliver any sequence that affects the expression of the GRIK2 gene in humans has been exclusively licensed from Regenxbio Inc. ("Regenxbio").” SEC filing
“Please see "-License and Collaboration Agreements-Clinical Product Candidates-REGENXBIO Inc." for a description of our license agreement with REGENXBIO Inc.” SEC filing
“Please see "-License and Collaboration Agreements-Clinical Product Candidates-REGENXBIO Inc." for a description of our license agreement with REGENXBIO Inc.” SEC filing
“License Agreement, dated as of November 19, 2018, by and between Rocket Pharmaceuticals, Ltd. and REGENXBIO Inc. (incorporated by reference to Exhibit 10.26 to the Company's Annual Report on Form 10-K (001-36829), filed with the SEC on March 8, 2019)” SEC filing
“...rials conducted by both Sarepta Therapeutics, Inc. and Capsida Biotherapeutics, Inc., respectively, and the occurrence of a brain tumor after an experimental gene therapy by REGENXBio Inc., may adversely impact how gene therapy is perceived by collaborators, regulators, and the investment community.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.